NEW YORK, June 29 (Reuters) - Alkermes (ALKS.O) beat back activist investor Sarissa Capital Management's boardroom challenge on Thursday when shareholders re-elected all of the biotechnology company's directors in one of the year's most closely watched votes.
But investors stuck by the company, which is valued at $5.4 billion, and returned all directors to their seats on the 11-member board.
Glass Lewis, ISS's smaller rival, recommended shareholders back all Alkermes directors.
Biogen shareholders this week elected Denner's romantic partner, Susan Langer, to fill his seat on the Biogen board after the board had nominated her.
Both ISS and Glass Lewis referenced the Biogen matter in their recommendations on how to vote at Alkermes.
Persons:
Alkermes, Nancy Wysenski, Sarah Schlesinger, Glass Lewis, Alex Denner, Susan Langer, Schlesinger, Sarissa, Svea Herbst, Bayliss, Chris Reese
Organizations:
YORK, Capital, Services, ISS, Svea, Thomson
Locations:
Alkermes, Biogen